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Abbreviations 23 
APC = Antigen-Presenting Cell 24 
CTL = Cytotoxic T Lymphocyte 25 
FSC = Forward Scatter 26 
OC = Ovarian Cancer 27 
PBMC = Peripheral Blood Mononuclear Cell 28 
SCC = Side Scatter 29 
TC = Cytotoxic T cell 30 
TCM = Central Memory T cell 31 
TEM = Effector Memory T cell 32 
TH = Helper T cell 33 
TIL = Tumor Infiltrating T cell 34 
TNaïve = Naïve T cell 35 
Treg = Regulatory T cell 36 
TTD = Terminally Differentiated T cell 37 
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Abstract 39 
Recently, a small subset of T cells that expresses the B cell marker CD20 has been identified in 40 
healthy volunteers and in patients with rheumatoid arthritis and multiple sclerosis. The origin of these 41 
CD20-positive T cells as well as their relevance in human disease remains unclear. Here, we 42 
identified that after functional B cell/T cell interaction CD20 molecules are transferred to the cell 43 
surface of T cells by trogocytosis together with the established trogocytosis marker HLA-DR. Further, 44 
the presence of CD20 on isolated CD20
+
 T cells remained stable for up to 48h of ex vivo culture. 45 
These CD20
+
 T cells almost exclusively produced IFN-γ (~70% vs. ~20% in the CD20
-
 T cell 46 
population) and were predominantly (CD8
+
) effector memory T cells (~60-70%). This IFN-γ producing 47 
and effector memory phenotype was also determined for CD20
+
 T cells as detected in the peripheral 48 
blood and ascitic fluids of ovarian cancer patients. In the latter, the percentage of CD20
+
 T cells was 49 
further strongly increased (from ~6% in peripheral blood to 23% in ascitic fluid).  50 
Taken together, the data presented here indicate that CD20 is transferred to T cells upon intimate T 51 
cell/B cell interaction. Further, CD20
+
 T cells are of memory and IFN-γ producing phenotype and are 52 
present in increased amounts in ascitic fluid of ovarian cancer patients. 53 
 54 
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Introduction 57 
Ovarian cancer (OC) remains the most deadly gynecological malignancy with a 5-year survival rate of 58 
only 45%.
1,2
 This poor prognosis is largely due to therapy-resistant relapses that occur in the majority 59 
of patients following first line therapy.
3,4
 Interestingly, a subset of patients appears to remain disease-60 
free for prolonged periods of time. To date, several factors have been identified that can be used to 61 
define this particular subset of patients with arguably the strongest prognostic indicator being early 62 
detection and treatment.
3,4
 In addition, studies by us and others have revealed strong links between 63 
anti-tumor immune responses and patient survival.
5–8
 Specifically, the presence of CD3
+
 and CD8
+
 64 
tumor-infiltrating lymphocytes (TIL) and their relative abundance versus regulatory T cells (Treg) is 65 
strongly associated with better survival.
7
 66 
In addition to Tumor-infiltrating T cells, it was recently shown that tumor-infiltrating CD20
+
 B cells 67 
(CD20
+
 TIL) are strongly associated with improved patient survival in high grade serous OC.
9
 Of note, 68 
these CD20
+
 B-cells were found to strongly co-localize with CD8+ cytolytic T-cells (CTLs), suggesting 69 
that these cells may work cooperatively to mediate antitumor immunity in OC.
10
 In this respect, it is 70 
worth noting that B cells can serve as antigen-presenting cells (APC) to T cells (reviewed in ref. 11). 71 
Indeed, under specific circumstances B-cel APCs can be more effective at antigen presentation than 72 
dendritic cells and may thus contribute to anti-OC immunity by providing local antigen presentation to 73 
T cells.
12
 74 
Indirect evidence for such antigen presentation of B to T cells in ovarian carcinoma might be obtained 75 
by evaluating intercellular exchange of membrane components between these two cell types, as 76 
several groups have recently demonstrated that antigen-loaded MHC class II molecules, specifically 77 
HLA-DR, can be transferred between various cells of the immune system during antigen presentation 78 
by a process known as trogocytosis.
13
 During trogocytosis, intact proteins, protein complexes and/or 79 
even membrane patches are transferred from one cell type to the other.
14–17
 In addition to HLA-DR 80 
transfer, other accessory molecules involved in this contact were found to be similarly transferred.
18
 81 
Interestingly, we and others have recently demonstrated the presence of a small population of T-cells 82 
that express the B-cell marker CD20 in the peripheral blood of healthy volunteers and patients 83 
suffering from rheumatoid arthritis.
19,20
 Based on this “hybrid” phenotype, we speculated that these 84 
cells might have acquired B cell membrane molecules during intercellular contact with B cells. 85 
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Therefore, we here set out to determine whether CD20
+
 T cells could originate as a result of B cell/T 86 
cell interaction and whether this population was present in patients with ovarian cancer, in particular in 87 
peripheral blood and in inflammatory ascites fluid. 88 
89 
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Results 90 
T cells acquire CD20 by trogocytosis and maintain a stable CD20-positive phenotype up to 48h 91 
after isolation 92 
Previous studies by us and others identified a subset of T cells that expressed the typical B cell 93 
marker CD20 
19,20
. The origin of such CD20
+
 T cells remains unclear, but they may arise as a result of 94 
intercellular membrane exchange during intimate T cell B cell interaction. In line with this, a CD19
-
 95 
CD3
+
 CD20
dim
 population of T-cells could be clearly identified (Figure 1A and S1A). In a panel of 10 96 
healthy volunteers, this CD20
+
 T-cell population comprised 6.0±3.8% of the total T cell population 97 
(Figure 1A). Importantly, the anti-CD20 antibody Rituximab fully specifically blocked CD20 on T cells 98 
as well as on B cells, confirming the specificity of the anti-CD20 antibody we used in identifying the T-99 
cell subpopulation (Figure S1B). Of note, in CD3
+
 T-cells isolated from cord blood this T-cell 100 
population was largely absent (Fig. 1B), which suggests that CD20
+
 cells may possibly arise later in 101 
life due to T cell / B cell interaction. Of note, presence of CD20  on the cell surface of CD20
+
 T celll 102 
population in the peripheral blood of adult healthy volunteers was stable, with CD20 presence being 103 
retained for up to 48h of culture of isolated CD20
+
 T cells (Figure 1C). Reversely, the sorted CD20
-
 T-104 
cell population remained CD20-negative during this time (Figure 1C).  105 
To determine whether transfer of CD20 from B cells to T cells could occur by trogocytosis, Jurkat 106 
leukemic T-cells were subsequently mixed with the B cell line Raji. In line with earlier studies, this co-107 
incubation triggered the rapid transfer of surface HLA-DR to Jurkat T-cells within 15 minutes (Fig. 1D) 108 
13
. Within the same time-frame, CD20 was similarly transferred to Jurkat cells albeit to a lesser extent 109 
(Fig. 1E). Of note, on these Jurkat cells the presence of CD20 was found concurrent with acquisition 110 
of HLA-DR (Fig. 1F). In control monocultures, Jurkat cells did not acquire CD20 or HLA-DR (data no 111 
shown). Thus, CD20 can be transferred from B-cells to leukemic T-cells in a time-frame of minutes.  112 
To further evaluate this possible mechanism for peripheral blood T-cells, PBMCs from healthy 113 
volunteers were isolated and mixed with the B cell line Z138, a cell line that expresses high levels of 114 
CD20. After 1h co-culture of PBMCs with Z138, the percentage of primary T cells that expressed 115 
CD20 increased from ~4% to ~30% (Fig. 1G). Similar co-incubation with B-cell Raji also induced 116 
transfer of CD20 to primary T-cells (Fig. 1G, 4% vs. 24%). Co-incubation of primary T-cells with 117 
primary HLA-mismatched B cells was associated with a reproducible increase of ~3% CD20
+
 T cells 118 
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(Fig. 1G).  As reported previously for B cells 
15
, trogocytosis was significantly reduced but still 119 
occurred when cells were co-cultured for 1h on ice (not shown). Finally, a small number of CD3
+
 T 120 
cells were found to co-express CD20 both in the human tonsil and in lymphoid-like structures in 121 
ovarian tumors (Figure 2A and B, respectively). These CD20
+
 T-cells were single cells (Figure 2C) 122 
and had the typical size of T-cells (Figure 2D), with B-cells being significantly larger (Figure 2E). 123 
CD20
+
 T-cells were always found in close proximity to B cells and several B cell : T cell pairs 124 
displayed an intimate membrane interaction (Figure 2A).  125 
 126 
CD20
+
 T cells are HLA-DR
+
 and CCR7
-
/CD45RO
+
 effector memory T cells in healthy volunteers 127 
and ovarian cancer (OC) patients 128 
The above data indicate that T-cells acquire CD20 molecules after B/T cell interaction, which 129 
suggests that CD20 should predominantly be found on memory T-cells. Therefore, the phenotype of 130 
circulating CD20
+
 T cells in peripheral blood from healthy volunteers and OC patients was further 131 
determined. CD20 within the T cell population was almost exclusively detected on effector memory T 132 
cells (TEM) in both healthy volunteers and OC patients (Figure 3A; 71.4±1.6% and Figure 5A; 133 
63.2±9.0%), as well as on terminally differentiated T cells (TTD, Figure 3A; 20.2±2.0% and Figure 5A; 134 
29.7±8.2%). Within this CD20
+
 TEM population, expression was skewed towards CD8
+
 cells over CD4
+
 135 
cells (Figure 3B; 60% vs. 40%). In contrast, CD20
-
 T cells displayed a distribution typically found in 136 
peripheral blood with naïve (30.9±9.6%), central memory (TCM; 9.1±2.4%), effector memory (TEM; 137 
39.9±1.6%) and terminally differentiated T-cells (TTD; 20.1±8.8%). Furthermore, CD20
-
 T cells 138 
contained a higher percentage of CD4
+
 T-cells than CD8
+
 T-cells (Figure S1C; 40% vs. 60%). 139 
Interestingly, CD20
+
 but not CD20
-
 T-cells also expressed HLA-DR on their cell surface (Figure 3C 140 
and S1D), consistent with the possible acquisition of cell membrane from antigen-presenting cells 141 
(APCs). Both CD20
+
 and CD20
-
 T cells expressed CD127 (IL-7R), but not CD25 (IL-2R) (Figure 3C 142 
and S1D). 143 
 144 
CD20
+
 T cells are IFN-γ  producing TH1/TC1 cells in healthy volunteers and OC patients 145 
To further characterize the CD20
+
 T cell population, intracellular cytokine stainings were performed to 146 
identify TH1/TC1, TH2/TC2 or TH17 cells. CD3
+
 PBMCs were stimulated with PMA/ionomycin in the 147 
presence of Brefeldin A and intracellular cytokine staining performed in conjunction with CD19, CD20 148 
8 
 
and CD45RO. As anticipated, non-gated CD3
+
 T cells as well as the CD20
-
 T-cell population 149 
contained both IFN-γ (Figure 4A), IL-4 (Figure 4B) and IL-17 (Figure 4C) producing cells, with 150 
CD45RO
+
 memory T cells being largely responsible for cytokine secretion (Figure 4A-C; left panels). 151 
However, within the CD20
+
 T cell population, that consisted of >95% CD45RO
+
 memory T-cells, 152 
almost all cells produced IFN-γ, with only a small percentage of cells that produced IL-4 and no IL-17 153 
production (Figure 4A-C). These findings were subsequently verified using multi-color fluorescent 154 
microscopy (Figure S2A). Of note, 4h stimulation with PMA/ionomycin did not shift CD45RA to 155 
CD45RO cells in these experiments (Figure S2B)  156 
 157 
The percentage of CD20
+
 T cells is increased in ascites fluid of ovarian cancer patients 158 
Patients with ovarian cancer had CD20
+
 T cell populations in the peripheral blood that closely 159 
matched that found in healthy volunteers, including a predominant TH1/TC1 TEM phenotype (Figure 160 
5A), with perhaps a minor trend towards a more TTD phenotype (Figure 5D). However, in peritoneal 161 
ascites fluid of OC patients the population of CD20
+
 T cells was significantly expanded and comprised 162 
approximately 23.4±6.8% of all ascites fluid T cells (Figure 5B; left panel and Figure 5C). These 163 
CD20
+
 ascites fluid T-cells were predominantly of TEM phenotype (Figure 5B and D) and were also 164 
skewed towards the TH1/TC1 cytokine production (Figure S3A-C). 165 
166 
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Discussion 167 
In the present study, we demonstrate that T cells rapidly acquired CD20 (<15 min.) when co-cultured 168 
in vitro with B cell leukemic lines or primary B-cells. In peripheral blood and in ascites fluid these 169 
CD20+ T cells were phenotypically characterized as effector memory T-cells that produced IFN-γ. 170 
Further, this CD20
+
 T-cell population was significantly enriched in ascites fluid in ovarian cancer 171 
patients. 172 
Data from the current study suggests that CD20
+
 T cells may arise as a result of membrane exchange 173 
upon T cell : B cell contact. These findings are consistent with the previously reported transfer of HLA-174 
DR from B cells to T cells 
13
. Concurrent with uptake of CD20 a similar uptake of HLA-DR by T cells 175 
was detected. It is therefore conceivable that CD20
+
 T cells originate following antigen-presentation 176 
by B cells and concomitant transfer of both HLA-DR and CD20 (and possibly other molecules). 177 
Indeed, the absence of CD20
+
 T cells in cord blood seems to support a role for the development of 178 
CD20
+
 T cells during immune responses later in life. 179 
In our cohort of healthy volunteers and OC patients (>30 individuals in total), approximately 2-10% 180 
(6.0±3.8%) of circulating T cells in the peripheral blood express CD20 on the T cell surface. 181 
Furthermore, multiple samplings of the same healthy volunteer in a 2 week interval revealed highly 182 
consistent levels of this subpopulation (data not shown). These findings are in line with other recent 183 
reports on the relative percentage of CD3
+
 CD20
+
 T cells in the peripheral blood of German and 184 
British cohorts of healthy volunteers and patients with rheumatoid arthritis 
19,20
. 185 
Importantly, as CD20 is considered a prototypical B cell marker, studies on CD20
+
 T cells should take 186 
exceptional care to exclude any contamination by B cell-T cell doublets. Indeed, Henry et al. have 187 
previously suggested that CD20
+
 T cells in peripheral blood may be an artifact of flow cytometry 188 
resulting from doublets.
21
 However, we and others have demonstrated that single isolated T cells can 189 
and do have CD20 molecules at their cell surface.
20
 Nevertheless, we addressed these concerns 190 
further in our current study in several ways. First, we have used a highly stringent gating strategy to 191 
exclude not only doublets (forward scatter pulse width area), but also B cells based on the co-192 
expression of CD19. Second, analysis of CD20
+
 T cell phenotype by confocal microscopy did not 193 
reveal any signs of B cell-T cell doublets, whereas we could clearly identify CD3
+
 CD20
+
 cells with 194 
CD20 levels distinct from a B cell (~10-100 fold lower). Third, CD3
+
 CD20
+ 
T cells could be isolated 195 
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from peripheral blood by single cell sorting, activated with a cocktail of anti-CD3 and IL-2 and 196 
remained a single homogenous population presenting CD20 and expressing typical T cell markers. 197 
Fourth, cord blood T cells were largely devoid of a CD3
+
 CD20
+ 
T cells under identical staining 198 
conditions. Fifth, B cell contamination in our phenotypical analysis should have resulted in a distinct 199 
population with characteristic B cell expression levels for CD45RO/CCR7/CD25/CD127/ HLA-DR, but 200 
no such population was observed. Therefore, we are confident of and support Wilk et al. on the 201 
validity of CD3
+
 CD20
+
 T cells in peripheral blood.
19
 202 
CD20
+
 T cells from peripheral blood were found to display a typical effector memory (TEM) phenotype 203 
and were skewed towards a CD8
+
 (~60%) Th1/Tc1 subtype. Furthermore, when performing 204 
phenotypical analysis of the CD20
+
 T cell subpopulation in the peripheral blood or ascites fluid of 205 
patients with ovarian cancer, we found that this phenotype was fully conserved within individuals with 206 
ovarian cancer. Of note, while Wilk et al. primarily examined T cell markers associated with activation 207 
status, their observed percentage of CD45RO expressing cells in CD20
+
 vs. CD20
-
 cells is almost 208 
identical to the one observed by us (Wilk et al. 72% vs. 42%; this study 76.7±1.9% vs. 49±2.4%) 
19,23
.  209 
As CD20
+
 T cells are predominantly TEM cells with a Tc1 (IFN-γ
+
 CD8
+
) phenotype, it is tempting to 210 
speculate that these cells function as a tumor suppressor population. Indeed, infiltration of TEM cells 211 
into ovarian cancer tumors has been correlated to improved disease progression and Tc1 cells have 212 
been extensively described as the main mediators of the anti-tumor T cell response.
6
 However, the 213 
relative levels of CD20
+
 T cells in ascites fluid were highly consistent and did not appear to correlate 214 
to disease stage, therapy response or expected prognosis. Alternatively, TEM cells and by extension 215 
CD20
+
 T cells might be expanded in the peritoneal cavity as a result of increased homing to peripheral 216 
tissues consistent with the function of TEM cells versus central memory T cells. 217 
One outstanding question that remains is whether there are functional differences between CD20
+
 218 
and CD20
-
 T-cells as a consequence of CD20 expression on the T-cell surface. On B-cells, CD20 219 
ligation by agonistic antibodies was reported to induce intracellular calcium fluxes and thereby to 220 
augment B-cell receptor signaling
24-26
. However, the natural ligand of CD20 is currently unknown and 221 
whether calcium signaling is the primary signal for CD20 in its natural context remains to be 222 
determined. In this respect, B cells from a juvenile patient with CD20 deficiency did not differ in basal 223 
calcium flux in response to treatment with IgG or IgM, but were defective in antibody production
27
. 224 
Further insight into the role of CD20 may help uncover whether CD20 has a function on CD20
+
 T-225 
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cells.   226 
In conclusion, we describe here the in depth characterization of CD20
+
 T cells from peripheral blood 227 
as CD8
+
 effector memory and IFN-γ producing T-cells. Further, we document a significant expansion 228 
of this population in the ascites fluid of patients with ovarian cancer and provide insights into the 229 
possible origin of these cells. Further studies should aim to elucidate whether CD20
+
 T cells occur de 230 
novo as a result of B cell antigen presentation in patients with OC and whether this T-cell population 231 
is involved in antigen-specific immunity against OC. 232 
233 
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Materials & Methods 234 
Antibodies and reagents 235 
Anti-CD3-CyQ, anti-CD3-PE, anti-CD4-PE, anti-CD8-PE, anti-CD19-PE, anti-CD20-FITC and anti-236 
HLA-DR-PE were from IQ products (Groningen, The Netherlands). Anti-CD45RO-APC, anti-CCR7-237 
PerCP-Cy5.5, anti-CD25-PE, anti-CD127-APC, anti-IFNy-PerCP-Cy5.5, anti-IL-4-PerCP-Cy5.5 and 238 
anti-IL-17A-PerCP-Cy5.5 were from eBioscience (San Diego, CA). Fluorescently-conjugated isotype 239 
controls for each antibody were ordered from the same companies as indicated above. The agonistic 240 
anti-CD3 antibody WT-32 was kindly provided by Dr. B.J. Kroesen (University of Groningen, The 241 
Netherlands). IL-2 was purchased from immunotools (Friesoythe, Germany). 242 
 243 
Cell lines and trogocytosis assays 244 
The T cell line Jurkat and B cell lines Z138 and Raji were purchased from the ATCC. Trogocytosis 245 
was assessed by co-culturing Jurkat or primary T cells with Z138 or Raji for various time points as 246 
indicated, followed by flow cytometric analysis of cell surface markers as described below. 247 
 248 
Isolation and activation of primary (patient-derived) immune cells 249 
Experiments were approved by the local Medical Ethical Committee and patients/healthy volunteers 250 
signed for informed consent. Peripheral blood lymphocytes (PBL) from blood of healthy donors or 251 
cancer patients were isolated using standard density gradient centrifugation (Lymphoprep; Axis-252 
Shield PoC As) as previously described.
22
 Tumor-associated immune cells were isolated from the 253 
primary ascites cultures using ammonium chloride lysis. Activated T cells were generated by culturing 254 
PBLs with anti-CD3 mAb WT-32 (0.5 μg/mL) and IL-2 (100 ng/mL) for 48 hours. Cord blood cells 255 
(following CD34
+
 depletion by magnetic cell sorting) were kindly provided by Prof. Dr. J.J. Schuringa 256 
(University of Groningen, The Netherlands) 257 
 258 
Cell surface immunofluorescence staining 259 
For determining the percentage of CD20
+
 T cells, 0.5x10
6
 cells per indicated condition were stained 260 
with anti-CD3-CyQ, anti-CD19-PE and anti-CD20-FITC. For phenotypic characterization of T cells, 261 
0.5x10
6
 cells per indicated condition were stained with anti-CD3-PE (or alternatively anti-CD4-PE or 262 
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anti-CD8-PE), anti-CD20-FITC, anti-CD45RO-APC and anti-CCR7-PerCP-Cy5.5. Expression of IL-263 
2Rα, IL-7Rα or HLA-DR was determined by staining 0.5x10
6
 cells per indicated condition with anti-264 
CD3-PerCP-Cy5.5, anti-CD20-FITC, anti-CD25-PE and anti-CD127-APC. All staining was carried out 265 
for 60 minutes on ice in the dark and specific staining of all indicated markers was confirmed using 266 
relevant isotype controls. Staining was analyzed on a BD Accuri C6 flow cytometre (Becton 267 
Dickinson). Data was plotted using Cflow software (Becton Dickinson). Positively and negatively 268 
stained populations were calculated by quadrant dot plot analysis. For all experiments, cells were 269 
carefully gated on forward scatter pulse width area to exclude doublets and B cells excluded from the 270 
analysis by co-expression of CD19. 271 
 272 
Intracellular immunofluorescence staining 273 
Immune cells were washed and stimulated with PMA/Ionomycin in the presence of brefeldin A for 4h. 274 
Subsequently, cells were washed in wash buffer (phosphate buffered saline, 5% fetal bovine serum, 275 
0.1% sodium azide) and stained with PE-conjugated anti-CD3, FITC-conjugated anti-CD20 and APC-276 
conjugated anti-CD45RO for 45 minutes on ice. Cells were subsequently fixed with Reagent A 277 
(Caltag, An Der Grab, Austria) for 10 minutes. After washing, cells were resuspended in 278 
permeabilization Reagent B (Caltag) and labeled with either anti-IFNy, anti-IL-4 or anti-IL-17A 279 
antibodies conjugated to PerCP-Cy5.5 for 20 minutes in the dark. Relevant isotype-matched 280 
antibodies were used as controls. After staining, the cells were washed and analyzed on a BD Accuri 281 
C6 flow cytometre (Becton Dickinson). Data was plotted using Cflow software (Becton Dickinson). 282 
Positively and negatively stained populations were calculated by quadrant dot plot analysis. 283 
 284 
Two-photon confocal microscopy 285 
Immune cells were stained essentially as described above for intracellular immunofluorescence with 286 
the exception that no anti-CD45RO-APC antibody was added during the initial cell surface staining 287 
after stimulation with PMA/Ionomycin. Cells were subsequently analyzed on an inverted LSM 780 288 
NLO Zeiss microscope (Axio Observer.Z1) with the kind help of Ing. K.A. Sjollema. 289 
 290 
Multi-color immunofluorescence on paraffin-embedded tissue 291 
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Tonsil and tumor slides were deparaffinized, rehydrated, and antigen retrieval was performed in a 292 
citrate buffer (10 mM citrate, pH 6.0). After cooling, endogenous peroxidase was blocked in a 0.3% 293 
H2O2 solution for 30 minutes. Slides were then incubated overnight with rat anti-human CD3 (Abcam, 294 
ab5690, 1:20) and mouse anti-human CD20 (DAKO, clone L26, 1:100). CD3 signal was visualized 295 
using a HRP-conjugated goat-anti-rat secondary antibody and Cy5 tyramide signal amplification 296 
according to the manufacturer’s instructions (PerkinElmer). CD20 was visualized using 297 
AlexaFluor488-conjugated goat anti-mouse secondary antibody. Counterstaining was done by 4',6-298 
diamidino-2-phenylindole (DAPI). Slides were mounted in Prolong Gold (Life Technologies) and 299 
stored in the dark at RT. Immunofluorescent slides were scanned using a TissueFaxs imaging system 300 
(TissueGnostics, Austria). Processed channels were merged using Adobe Photoshop. 301 
 302 
Statistical analysis 303 
Data reported are mean values ± SD of at least three independent experiments. Statistical analysis 304 
was performed by one-way ANOVA followed by Tukey-Kramer post test or, where appropriate, by 305 
two-sided unpaired Student’s t-test. p < 0.05 was defined as a statistically significant difference. 306 
Where indicated * = p<0.05; ** = p<0.01; *** = p<0.001. 307 
308 
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Figure legends 398 
Figure 1. T cells can acquire CD20 upon co-culture with B cells. A-B Peripheral blood of healthy 399 
volunteers (A) or cord blood (B) was stained using anti-CD3-CyQ, anti-CD19-PE and anti-CD20-FITC. 400 
Plots represent cells gated on FSC/SSC followed by exclusion of B-cells based on co-expression of 401 
CD19 and CD20. C PBMCs from healthy volunteers were stained using anti-CD3-CyQ, anti-CD19-PE 402 
and anti-CD20-FITC and CD20
-
 and CD20
+
 T cell populations isolated using multicolor cell sorting. 403 
Isolated cells were left untreated or activated using a cocktail of anti-CD3 mAb and IL-2 for 48h after 404 
which cells were examined for CD3 and CD20 expression. D-F Jurkat T cells were co-cultured with 405 
CD20
+
 B cell line Raji for 15 minutes and expression of HLA-DR (D), CD20 (E) or both (F) was 406 
assessed by flow cytometry on gated CD3
+
 T-cells. G PBMCs of healthy volunteers were incubated 407 
alone or in the presence of Z138, Raji or healthy control B cells at a ratio of 2-1 for 1h followed by flow 408 
cytometric analysis for CD20 expression within the CD3
+
 population. Asterisks represent significant 409 
changes compared to PBMCs alone.  410 
 411 
Figure 2. In situ identification of CD3
+
 CD20
+
 T-cells. A Tonsil and B ovarian tumor tissue was 412 
stained for CD3 and CD20 and co-expression assessed by multicolor immunofluorescent microscopy. 413 
Insets identify the region were individual CD3
+
 CD20
+
 T cells could be identified. C single cell 414 
expression of CD3 and CD20 was validated using counterstaining with DAPI. D CD20
-
 CD3
+
 T-cells 415 
and E CD20
+
 CD3
-
 B cells could also be readily identified. 416 
 417 
Figure 3. Phenotype of CD20
+
 T-cells. A PBMCs from healthy volunteers were stained using anti-418 
CD3-CyQ, anti-CD19-PE and anti-CD20-FITC and prevalence of T cell subpopulations assessed 419 
using flow cytometry. PBMCs were strictly gated on FSC/SSC to exclude B/T doublets (left panel) and 420 
B cells excluded from analysis after identification based on co-expression of CD19 and CD20 (middle 421 
panel). B PBMCs from healthy volunteers were stained using anti-CD3-PE, anti-CD20-FITC, anti-422 
CD45RO-APC and anti-CCR7-PerCP-Cy5.5 mAbs and analyzed using flow cytometry. C PBMCs 423 
from healthy volunteers were stained using anti-CD20-FITC, anti-CD45RO-APC and anti-CCR7-424 
PerCP-Cy5.5 (left panel) in combination with either anti-CD4-PE (middle panel) or anti-CD8-PE (right 425 
panel) mAbs and analyzed using flow cytometry. Middle and right panels are gated on the CD20
+
 T 426 
cells. D CD20
+
 T cells identified as described in A were further characterized for expression of CD25 427 
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(left panel), CD127 (middle panel) or HLA-DR (right panel) using flow cytometry. Percentages±SD are 428 
representative of 7 healthy donors. 429 
 430 
Figure 4. Cytokine production by CD20
+
 T cells. PBMCs from healthy volunteers were stimulated 431 
for 4h using PMA/Ionomycin in the presence of Brefeldin A and intracellular production of IFN-γ (A), 432 
IL-4 (B) and IL-17A (C) assessed in the CD3
+
 CD20
-
 and CD3
+
 CD20
+ 
populations assessed using 433 
flow cytometry. Anti-CD45RO-APC was included to identify memory T cell populations. 434 
 435 
Figure 5. Prevalence and subtype of CD20
+
 T-cells in patients with ovarian cancer. PBMCs (A) 436 
or ascites fluid cells (B) from patients with ovarian cancer were stained using anti-CD3-PE, anti-437 
CD20-FITC, anti-CD45RO-APC and anti-CCR7-PerCP-Cy5.5 mAbs and analyzed using flow 438 
cytometry. C-D Percentages (C) and subset distribution (D) of CD20
+
 T cells in peripheral blood of 439 
healthy volunteers, peripheral blood of patients with ovarian cancer and in ascites fluid of ovarian 440 
cancer. Data were analyzed as described in the legend to Figure 1. 441 
442 
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Supplementary Figure legends 443 
Figure S1. Phenotype of CD20
+
 T-cells. A PBMCs from healthy volunteers were stained using anti-444 
CD3-CyQ, anti-CD19-PE and anti-CD20-FITC (left panel) or anti-CD3-CyQ, FITC-labeled isotype 445 
control and PE-labeled isotype control (middle and right panel) and analyzed using flow cytometry. 446 
PBMCs were strictly gated on FSC/SSC to exclude B/T doublets (Figure 3; left panel). B PBMCs from 447 
healthy volunteers were left untreated or treated on ice for 45 minutes with anti-CD20 antibody 448 
Rituximab followed by staining using using anti-CD3-CyQ, anti-CD19-PE and anti-CD20-FITC mAbs 449 
and analyzed using flow cytometry. C PBMCs from healthy volunteers were stained using anti-CD20-450 
FITC, anti-CD45RO-APC and anti-CCR7-PerCP-Cy5.5 (left panel) in combination with either anti-451 
CD4-PE (middle panel) or anti-CD8-PE (right panel) mAbs and analyzed using flow cytometry. Middle 452 
and right panels are gated on the CD20
-
 T cells. D CD20
-
 T cells identified as described in Figure 3A 453 
were further characterized for expression of CD25 (left panel), CD127 (middle panel) or HLA-DR (right 454 
panel) using flow cytometry. Percentages±SD are representative of 7 healthy donors. 455 
 456 
Figure S2. Phenotype and cytokine production of CD20
+
 T-cells. A PBMCs from healthy 457 
volunteers were stained for CD3, CD20 and IFN-γ and analyzed using confocal microscopy. B 458 
PBMCs from healthy volunteers were stimulated for 4h using PMA/Ionomycin in the presence of 459 
Brefeldin A or left untreated, and expression of CD45RO within the CD3
+
 population assessed by flow 460 
cytometry. 461 
 462 
Figure S3. Cytokine production by CD20
+
 T cells from ascites fluid. Cells from ascites fluid 463 
derived from a patient with ovarian cancer were stimulated for 4h using PMA/Ionomycin in the 464 
presence of Brefeldin A and intracellular production of IFN-γ (A), IL-4 (B) and IL-17A (C) assessed in 465 
the CD3
+
 CD20
-
 and CD3
+
 CD20
+ 
populations assessed using flow cytometry. Anti-CD45RO-APC 466 
was included to identify memory T cell populations. 467 
